SCHEMBL4806476

SCHEMBL4806476

CC(=O)NCCc1ncc(F)cc1F

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AGBL2 Q5U5Z8 1/20 0.43
QPCT Q16769 1/20 0.42
QPCTL Q9NXS2 1/20 0.42
MTNR1A P48039 8/20 0.41
MTNR1B P49286 7/20 0.41
NOTUM Q6P988 1/20 0.41
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
PTGS1 P23219 1/20 0.40
BLM P54132 1/20 0.40
HIF1A Q16665 1/20 0.40
HSD17B10 Q99714 1/20 0.40
F13A1 P00488 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12476826 0.85 MTNR1B (0.40) QPCTQPCTLMTNR1AMTNR1BKDM4E
SCHEMBL1396181 0.78 QPCT (0.47) QPCTQPCTLMTNR1AMTNR1BNOTUM
SCHEMBL29329085 0.75 AGBL2 (0.53) AGBL2KDM4E
SCHEMBL4749498 0.73 ACACB (0.54) QPCTQPCTLMTNR1AMTNR1BNOTUM
SCHEMBL10115987 0.72 AGBL2 (0.41) AGBL2KDM4EHSD17B10
SCHEMBL4973249 0.72 AGBL2 (0.41) AGBL2
Acetic Acid SCHEMBL28002626 0.71 AGBL2 (0.49) AGBL2
SCHEMBL21801325 0.71 AGBL2 (0.49) AGBL2KDM4EALDH1A1LMNAMAPT
SCHEMBL2947631 0.71 AGBL2 (0.36) AGBL2KDM4EALDH1A1MAPTHIF1A
SCHEMBL29877399 0.70 AGBL2 (0.38) AGBL2BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899323-A2 PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS AstraZeneca AB (SE) 2008-03-19 EP disclosed
WO-2006123113-A2 PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS ASTRAZENECA AB (SE) 2006-11-23 WO disclosed